Comparison Chart Exelixis, Inc. Börse Stuttgart
Stocks
EX9
US30161Q1040
Biotechnology & Medical Research
|
Market Closed -
Börse Stuttgart
15:46:10 2026-08-25 EDT
|
5-day change | 1st Jan Change | ||
| 48.24 EUR | +3.16% |
|
+3.68% | +23.13% |
| 08-05 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-05 | (EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +3.16% | +3.68% | - | - | - | 13.52B |
-
|
-
|
-
|
- Stock Market
- Stocks
- EXEL Stock
- EX9 Stock
- Charts Exelixis, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
